Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Helsinn at the 31st Annual J.P. Morgan Healthcare Conference, January 8, 2013

January 7, 2013

LUGANO, Switzerland, January 7, 2013 /PRNewswire/ –

Helsinn Group is pleased to announce that tomorrow (Tuesday, January 8th, 2013) at 9am
Pacific Standard Time (18:00 Swiss time), Dr. Riccardo Braglia, Helsinn Group CEO, will
present an overview of the Helsinn group, its products and corporate goals at the 31st
Annual J.P. Morgan Healthcare Conference, San Francisco.

Dr. Braglia’s presentation will be shared with an audience of institutional investors,
venture-capitalist companies, global industry leaders, innovative technology creators,
private investors, industry executives, business development executives and private equity
firms.

Approximately 300 companies are expected to present at this most important healthcare
investment conference.

Dr. Braglia’s presentation will be webcast and can be accessed for the next three
months at the following direct link:

http://www.presseportal.ch/go2/jpmorgan.metameetings.com

About Helsinn Group

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano,
Switzerland, and operating subsidiaries in Ireland and the United States. Helsinn’s
business model is focused on the licensing of pharmaceuticals, medical devices and
nutritional supplement products in therapeutic niche areas. Helsinn is an important player
in cancer supportive care. Helsinn Group in-licenses early-to-late stage new chemical
entities, completes their development through the performance of pre-clinical /clinical
studies and Chemistry, Manufacturing, and Control (CMC) development, and files and attains
their market approvals worldwide. Helsinn’s products are out-licensed to its network of
local marketing and commercial partners, selected for their deep in-market knowledge and
know-how whom Helsinn assists and supports by providing a full range of product and
scientific management services, including commercial, regulatory, financial, legal, and
medical marketing advice. The active pharmaceutical ingredients and the finished products
are manufactured according to the highest quality, safety, and environmental standards at
Helsinn’s GMP facilities in Switzerland and Ireland and supplied worldwide to its
customers.

Further information on Helsinn Group is available at http://www.helsinn.com

        For Helsinn Group
        Paola Bonvicini
        Head of Communication & Press Office
        PH +41-91-985-21-21
        Info-hhc@helsinn.com

SOURCE Helsinn SA


Source: PR Newswire